reMYND

Gaston Geenslaan 1
3001 Leuven
BE
reMYND
Foundation date
07/02/2002
Sector
#Biotechnology - TherapeuticsSubsector
- #Therapeutics - Small molecules
- #R&D Services - CRO (Contract Research Organization)
- #R&D Services - Screening
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the nervous system
- #Endocrine - nutritional and metabolic diseases
reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
2206 '23
Translational Research in Crops
Event by: VIB
Latest news
More news-
Mithra appoints experienced life sciences executive Christian Homsy* as Chairman
19 hours ago
Read more
-
Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema
Friday May 26th 2023
Read more
-
How garbage disposal clogs in cells can lead to Alzheimer’s
Friday May 26th 2023
Read more